Pirenzepine (dihydrochloride)

Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells[1][2].

Product Specifications

CAS Number

[29868-97-1]

Product Name Alternative

LS 519; Pirenzepin (dihydrochloride) ; Gastrozepin (dihydrochloride)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

MAChR

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Pirenzepine_dihydrochloride.html

Concentration

10mM

Purity

99.93

Solubility

H2O : 50 mg/mL (ultrasonic)

Smiles

O=C1NC2=CC=CN=C2N(C(CN3CCN(C)CC3)=O)C4=CC=CC=C14.[H]Cl.[H]Cl

Molecular Formula

C19H23Cl2N5O2

Molecular Weight

424.32

Precautions

H302, H315, H319, H335

References & Citations

[1]Carmine AA, et al. Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases. Drugs. 1985 Aug;30 (2) :85-126.|[2]Yin QQ, et al. Muscarinic acetylcholine receptor M1 mediates prostate cancer cell migration and invasion through hedgehog signaling. Asian J Androl. 2018 Nov-Dec;20 (6) :608-614.|[3]Yabuki Y, et al. The T-type calcium channel enhancer SAK3 inhibits neuronal death following transient brain ischemia via nicotinic acetylcholine receptor stimulation. Neurochem Int. 2017 Sep;108:272-281.